Skip to main content
Premium Trial:

Request an Annual Quote

Cornell, Hebrew University, Tel Aviv University, and Stanford Complete Licensing Deals

Premium
Following is a summary of notable biotechnology and life sciences licensing deals announced last week between academic or non-profit research institutions and private entities:
 
 
Licensing Institution: Cornell University
 
Primary Inventor: John Savarese, chairman, department of anesthesiology, Weill Cornell Medical Center
 
Licensee: Avera Pharmaceuticals, San Diego
 
Technology: Avera has licensed two compounds from Cornell. The first, AV002, is an intermediate-acting, non-depolarizing, neuromuscular blocking compound in late preclinical development as a surgical muscle relaxant. The second compound is a preoprietary reversal agent that reverses neuromuscular blockade.
 

 
Licensing Institutions: Hebrew University of Jerusalem and Tel Aviv University, Israel
 
Primary Inventors: Hillel Bercovier and Ayelet Barenholz, professors, Hebrew University; and Jonathan Gershoni, professor, Tel Aviv University
 
Licensee: BioLineRx, Jerusalem, Israel
 
Technology: BL-4020, a peptide designed to function as an anti-inflammatory agent in various inflammatory diseases such as allergic asthma and colitis. The peptide mimics ManLAM, a protein from the cell surface of Mycobacterium tuberculosis.
 

 
Licensing Institution: Stanford University School of Medicine, Stanford, CA
 
Primary Inventor: Michelle Calos, associate professor of genetics, Stanford University School of Medicine
 
Licensee: Pain Therapeutics
 
Technology: Gene integration technology that may be able to replace daily or weekly protein replacement therapy with a single, lasting procedure that promotes normal blood coagulation in hemophilic patients.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.